Skip to main content

Titan Pharmaceuticals, Inc. (TTNP)

NASDAQ: TTNP · IEX Real-Time Price · USD
1.81
+0.06 (3.43%)
After-hours:Oct 22, 2021 7:04 PM EDT
1.75
-0.04 (-2.23%)
At close: Oct 22, 4:00 PM
Market Cap17.21M
Revenue (ttm)3.30M
Net Income (ttm)-12.34M
Shares Out9.86M
EPS (ttm)-1.74
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume111,440
Open1.77
Previous Close1.79
Day's Range1.72 - 1.81
52-Week Range1.57 - 8.85
Beta0.86
AnalystsBuy
Price Target7.00 (+300.0%)
Est. Earnings DateNov 15, 2021

About TTNP

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program, TP-2021 for use in combination with ProNeura technology for treatment ...

IndustryPharmaceuticals
IPO DateJan 18, 1996
Employees12
Stock ExchangeNASDAQ
Ticker SymbolTTNP
Full Company Profile

Financial Performance

In 2020, TTNP's revenue was $4.84 million, an increase of 85.72% compared to the previous year's $2.61 million. Losses were -$18.24 million, 10.8% more than in 2019.

Financial Statements

Analyst Forecast

According to one analyst, the rating for TTNP stock is "Buy" and the 12-month stock price forecast is 7.00.

Price Target
$7.00
(300.00% upside)
Analyst Consensus: Buy

News

Titan Pharmaceuticals and MUSC FRD Enter Into Research and Option License Agreement

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a research and option license ag...

1 week ago - PRNewsWire

Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic ...

SOUTH SAN FRANCISCO, Calif., June 23, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that the in vivo study of its human kappa-opioid receptor agonist ("TP-2021," former...

3 months ago - PRNewsWire

Titan Pharmaceuticals Announces Filing Of 2020 Annual Report On Form 10-K

SOUTH SAN FRANCISCO, Calif., March 31, 2021 /PRNewswire/ --  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has filed its annual report on Form 10-K for the fiscal year ended Decembe...

6 months ago - PRNewsWire

Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Develo...

SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potenc...

8 months ago - PRNewsWire

Titan Pharmaceuticals Announces Pricing of $9.7 Million Registered Direct Offering

SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with certain accredited institut...

9 months ago - PRNewsWire

Titan Pharmaceuticals Announces Reverse Stock Split

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that its Board of Directors has approved a 1-for-30 rever...

10 months ago - PRNewsWire

TTNP Stock Price Increases 34.75%: Why It Happened

The stock price of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) has increased by 34.75% from $0.13 per share to $0.17 per share. This is an explanation of why it happened.

11 months ago - Pulse2

Titan Pharmaceuticals Reports Third Quarter 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the third quarter ended September 30...

11 months ago - PRNewsWire

7 Penny Stocks to Watch in November

Penny stocks have become a popular investment alternative in 2020's volatile corona-economy. Here's a look at 7 penny stock to watch in November.

Other symbols:CIDMDVAXNOKWTRH
11 months ago - InvestorPlace

Titan Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced the pricing of an underwritten public offering of 80,000,000 units at a price of $0....

11 months ago - PRNewsWire

Titan Pharmaceuticals News: 8 Things for TTNP Stock Investors to Know about the JT Pharma Deal

Titan Pharmaceuticals (TTNP) is making news on Wednesday after announcing a deal with JT Pharma to acquire one of its assets. The post Titan Pharmaceuticals News: 8 Things for TTNP Stock Investors to Kn...

11 months ago - InvestorPlace

Titan Pharmaceuticals Announces Debt Settlement Agreement with Molteni and Horizon

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing...

11 months ago - PRNewsWire

Titan Pharmaceuticals' Stockholders Approve Proposal To Amend Its Certificate Of Incorporation

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced that, at today's special meeting, its stockholders approved th...

1 year ago - PRNewsWire

Titan Pharmaceuticals Provides Update To Stockholders On Proposal To Amend Its Certificate Of Incorporation

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.

1 year ago - PRNewsWire

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q2 2020 Results - Earnings Call Transcript

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q2 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Titan Pharmaceuticals Reports Second Quarter 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.

1 year ago - PRNewsWire

Titan Pharmaceuticals To Report Second Quarter 2020 Financial Results On August 14, 2020

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.

1 year ago - PRNewsWire

Titan Pharmaceuticals Urges Stockholders to Vote "FOR" Proposal to Amend Its Certificate of Incorporation

SOUTH SAN FRANCISCO, Calif., July 8, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today urged its stockholders to vote "FOR" an amendment to its certificate...

1 year ago - PRNewsWire

Titan Pharmaceuticals And Indegene Enter Into Probuphine® Co-Promotion Partnership

SAN FRANCISCO, June 24, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a co-promotion partnership with Indegene Inc. ...

1 year ago - PRNewsWire

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q1 2020 Results - Earnings Call Transcript

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Titan Pharmaceuticals Reports First Quarter 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., May 15, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the first quarter ended March 31, 202...

1 year ago - PRNewsWire

Penny Stocks to Buy Using Technical Analysis for April 2020

In a volatile market, it's more important than ever to hone your technical analysis skills. Here are some near-term trading ideas.

Other symbols:ALIMCPIXOSGRRTS
1 year ago - Investopedia

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q4 2019 Results - Earnings Call Transcript

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q3 2019 Results - Earnings Call Transcript

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q2 2019 Results - Earnings Call Transcript

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q2 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha